Clinical and Imaging Findings in Children with Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD): From Presentation to Relapse

REFERENCES

1. 1.↵
   1. O’Connor KC,
   2. McLaughlin KA,
   3. De Jager PL, et al

   . Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211–17 doi:10.1038/nm1488 pmid:17237795

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Reindl M,
   2. Waters P

   . Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15:89–102 doi:10.1038/s41582-018-0112-x pmid:30559466

   CrossRefPubMed
3. 3.↵
   1. de Mol CL,
   2. Wong YY,
   3. van Pelt ED, et al

   . Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study. J Neurol 2018;265:1310–19 doi:10.1007/s00415-018-8835-6 pmid:29569176

   CrossRefPubMed
4. 4.↵
   1. Hennes EM,
   2. Baumann M,
   3. Schanda K

   , BIOMARKER Study Group, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017;89:900–08 doi:10.1212/WNL.0000000000004312 pmid:28768844

   CrossRefPubMed
5. 5.↵
   1. Hacohen Y,
   2. Wong YY,
   3. Lechner C, et al

   . Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018;75:478–87 doi:10.1001/jamaneurol.2017.4601 pmid:29305608

   CrossRefPubMed
6. 6.↵
   1. Hacohen Y,
   2. Banwell B

   . Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol 2019;21:2 doi:10.1007/s11940-019-0541-x pmid:30671648

   CrossRefPubMed
7. 7.↵
   1. Lopez-Chiriboga AS,
   2. Majed M,
   3. Fryer J, et al

   . Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 2018;75:1355–63 doi:10.1001/jamaneurol.2018.1814 pmid:30014148

   CrossRefPubMed
8. 8.↵
   1. Jarius S,
   2. Ruprecht K,
   3. Kleiter I

   , Neuromyelitis Optica Study Group (NEMOS), et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. 1. Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016;13:279 doi:10.1186/s12974-016-0717-1 pmid:27788675

   CrossRefPubMed
9. 9.↵
   1. Armangue T,
   2. Olive-Cirera G,
   3. Martinez-Hernandez E

   , Spanish Pediatric anti-MOG Study Group, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020;19:234–46 doi:10.1016/S1474-4422(19)30488-0 pmid:32057303

   CrossRefPubMed
10. 10.↵
    1. Fernandez-Carbonell C,
    2. Vargas-Lowy D,
    3. Musallam A, et al

    . Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 2016;22:174–84 doi:10.1177/1352458515587751 pmid:26041801

    CrossRefPubMed
11. 11.↵
    1. Wegener-Panzer A,
    2. Cleaveland R,
    3. Wendel EM, et al

    . Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurol Neuroimmunol Neuroinflamm 2020;7:e731 doi:10.1212/NXI.0000000000000731

    Abstract/FREE Full Text
12. 12.↵
    1. Hennes EM,
    2. Baumann M,
    3. Lechner C, et al

    . MOG spectrum disorders and role of MOG-antibodies in clinical practice. Neuropediatrics 2018;49:3–11 doi:10.1055/s-0037-1604404 pmid:28859212

    CrossRefPubMed
13. 13.↵
    1. Xu J,
    2. Liu L,
    3. Xiong J, et al

    . The clinical, radiologic, and prognostic differences between pediatric and adult patients with myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis. Front Neurol 2021;12:679430 doi:10.3389/fneur.2021.679430 pmid:34093424

    CrossRefPubMed
14. 14.↵
    1. Baumann M,
    2. Bartels F,
    3. Finke C

    , E.U. Paediatric MOG Consortium, et al. E.U. Paediatric MOG Consortium Consensus: 2. Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 2020;29:14–21 doi:10.1016/j.ejpn.2020.10.002 pmid:33158737

    CrossRefPubMed
15. 15.↵
    1. Baumann M,
    2. Grams A,
    3. Djurdjevic T, et al

    . MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol 2018;265:845–55 doi:10.1007/s00415-018-8781-3 pmid:29423614

    CrossRefPubMed
16. 16.↵
    1. Baumann M,
    2. Sahin K,
    3. Lechner C, et al

    . Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86:265–72 doi:10.1136/jnnp-2014-308346 pmid:25121570

    Abstract/FREE Full Text
17. 17.↵
    1. Konuskan B,
    2. Yildirim M,
    3. Gocmen R, et al

    . Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. Mult Scler Relat Disord 2018;26:1–7 doi:10.1016/j.msard.2018.07.022 pmid:30212767

    CrossRefPubMed
18. 18.↵
    1. Banwell B,
    2. Bennett JL,
    3. Marignier R, et al

    . Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023;22:268–82 doi:10.1016/S1474-4422(22)00431-8 pmid:36706773

    CrossRefPubMed
19. 19.↵
    1. Lui A,
    2. Chong J,
    3. Flanagan E, et al

    . High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics. Mult Scler Relat Disord 2021;56:103253 doi:10.1016/j.msard.2021.103253 pmid:34517190

    CrossRefPubMed
20. 20.↵
    1. Tantsis EM,
    2. Prelog K,
    3. Alper G

    , Paediatric Myelitis MRI Study Group, et al. Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children. Dev Med Child Neurol 2019;61:1108–16 doi:10.1111/dmcn.14114 pmid:30537075

    CrossRefPubMed
21. 21.↵
    1. Salama S,
    2. Khan M,
    3. Levy M, et al

    . Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult Scler Relat Disord 2019;29:15–22 doi:10.1016/j.msard.2019.01.021 pmid:30658259

    CrossRefPubMed
22. 22.↵
    1. Dubey D,
    2. Pittock SJ,
    3. Krecke KN, et al

    . Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019;76:301–09 doi:10.1001/jamaneurol.2018.4053 pmid:30575890

    CrossRefPubMed
23. 23.↵
    1. Cobo-Calvo A,
    2. Ruiz A,
    3. D’Indy H, et al

    . MOG antibody-related disorders: common features and uncommon presentations. J Neurol 2017;264:1945–55 doi:10.1007/s00415-017-8583-z pmid:28770374

    CrossRefPubMed
24. 24.↵
    1. Garbugio Dutra B,
    2. da Rocha AJ,
    3. Hoffmann Nunes R, et al

    . Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis. Radiographics 2018;38:169–193 doi:10.1148/rg.2018184002 pmid:29528835

    CrossRefPubMed
25. 25.↵
    1. Song H,
    2. Zhou H,
    3. Yang M, et al

    . Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China. J Neurol Sci 2019;400:83–89 doi:10.1016/j.jns.2019.03.014 pmid:30904690

    CrossRefPubMed
26. 26.↵
    1. Wendel EM,
    2. Baumann M,
    3. Barisic N, et al

    . High association of MOG-IgG antibodies in children with bilateral optic neuritis. Eur J Paediatr Neurol 2020;27:86–93 doi:10.1016/j.ejpn.2020.04.002 pmid:32327391

    CrossRefPubMed
27. 27.↵
    1. Sato DK,
    2. Callegaro D,
    3. Lana-Peixoto MA, et al

    . Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474–81 doi:10.1212/WNL.0000000000000101 pmid:24415568

    Abstract/FREE Full Text
28. 28.↵
    1. Kitley J,
    2. Waters P,
    3. Woodhall M, et al

    . Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276–83 doi:10.1001/jamaneurol.2013.5857 pmid:24425068

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Wang C,
    2. Narayan R,
    3. Greenberg B

    . Anti-myelin oligodendrocyte glycoprotein antibody associated with gray matter predominant transverse myelitis mimicking acute flaccid myelitis: a presentation of two cases. Pediatr Neurol 2018;86:42–45 doi:10.1016/j.pediatrneurol.2018.06.003 pmid:30077551

    CrossRefPubMed
30. 30.↵
    1. Ramanathan S,
    2. Mohammad S,
    3. Tantsis E

    , Australasian and New Zealand MOG Study Group, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018;89:127–37 doi:10.1136/jnnp-2017-316880 pmid:29142145

    Abstract/FREE Full Text
31. 31.↵
    1. Waters P,
    2. Fadda G,
    3. Woodhall M

    , Canadian Pediatric Demyelinating Disease Network, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 2020;77:82–93 doi:10.1001/jamaneurol.2019.2940 pmid:31545352

    CrossRefPubMed